For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not ...

You’ve likely heard the hype around Ozempic and Wegovy – weight loss drugs that have taken the world by storm. These ...

Glucagon-like peptide-1 receptor agonists are tied to a reduction in alcohol intake in patients being treated for obesity.

Understanding the goals of your patients can help alleviate some pushback from the start of an appointment.

Data-driven clustering reveals distinct obesity phenotypes with unique clinical, behavioral, microbiome features, and differential GLP-1 responses.

While medications like Wegovy promise quick results, many people still prefer a drug-free path to shedding pounds. Science ...

New research presented May 17 at the American Psychiatric Association's Annual Meeting shows that GLP-1 receptor agonists may ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being ...

This study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in ...

Patients taking a GLP-1 for diabetes have a lower risk for AF at 3 years than those on other medications, report ...

First-generation GLP-1 drugs like liraglutide (Saxenda) and exenatide (Byetta) were associated with a 41% lower risk of ...